Journal of Applied Physiology Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 101: 898-905, 2006. First published May 18, 2006; doi:10.1152/japplphysiol.00126.2006
8750-7587/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
101/3/898    most recent
00126.2006v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendias, C. L.
Right arrow Articles by Faulkner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendias, C. L.
Right arrow Articles by Faulkner, J. A.

Contractile properties of EDL and soleus muscles of myostatin-deficient mice

Christopher L. Mendias,1 James E. Marcin,2 Daniel R. Calerdon,3 and John A. Faulkner1,2

Departments of 1Molecular and Integrative Physiology, 2Biomedical Engineering, and 3Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan

Submitted 2 February 2006 ; accepted in final form 10 May 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Myostatin is a negative regulator of muscle mass. The impact of myostatin deficiency on the contractile properties of healthy muscles has not been determined. We hypothesized that myostatin deficiency would increase the maximum tetanic force (Po), but decrease the specific Po (sPo) of muscles and increase the susceptibility to contraction-induced injury. The in vitro contractile properties of extensor digitorum longus (EDL) and soleus muscles from wild-type (MSTN+/+), heterozygous-null (MSTN+/–), and homozygous-null (MSTN–/–) adult male mice were determined. For EDL muscles, the Po of both MSTN+/– and MSTN–/– mice were greater than the Po of MSTN+/+ mice. For soleus muscles, the Po of MSTN–/– mice was greater than that of MSTN+/+ mice. The sPo of EDL muscles of MSTN–/– mice was less than that of MSTN+/+ mice. For soleus muscles, however, no difference in sPo was observed. Following two lengthening contractions, EDL muscles from MSTN–/– mice had a greater force deficit than that of MSTN+/+ or MSTN+/– mice, whereas no differences were observed for the force deficits of soleus muscles. Myostatin-deficient EDL muscles had less hydroxyproline, and myostatin directly increased type I collagen mRNA expression and protein content. The difference in the response of EDL and soleus muscles to myostatin may arise from differences in the levels of a myostatin receptor, activin type IIB. Compared with the soleus, the amount of activin type IIB receptor was approximately twofold greater in EDL muscles. The results support a significant role for myostatin not only in the mass of muscles but also in the contractility and the composition of the extracellular matrix of muscles.

GDF-8; muscle morphology; muscle injury

MYOSTATIN (GDF-8) IS A MEMBER of the transforming growth factor-beta (TGF-beta) family of cytokines and functions as a negative regulator of skeletal muscle mass. Inactivation of the myostatin genes and postnatal inhibition of myostatin both result in significant increases in skeletal muscle mass (4, 5, 21, 42, 47, 65, 68, 69). Systemic and skeletal muscle-specific overexpression of myostatin induce skeletal muscle atrophy (52, 71). The Belgian Blue and Piedmontese breeds of cattle have a mutated form of the myostatin gene and are characterized by larger skeletal muscles than other breeds (20, 24). At the time of birth, a human child with apparent null mutations in his myostatin genes had a thigh muscle volume twofold greater in size than 10 age-matched controls (54). The child's mother, who is heterozygous for the mutation, was also reported to be hypermuscular (54).

Myostatin circulates through the blood in a latent form bound to its propeptide and to follistatin (2). The myostatin gene (MSTN) encodes a precursor protein that undergoes proteolytic processing to generate a propeptide and a mature myostatin dimer (67). The propeptide binds myostatin noncovalently and inhibits the bioactivity of myostatin (42, 57, 67). Cleavage of the propeptide by the bone morphogenic protein-1/tolloid family of metalloproteinases results in the liberation and activation of myostatin (67). Activated myostatin binds to the activin type IIB (ActRIIB) and IB (ActRIB) receptors to initiate the Smad2/3 and p38 MAPK intercellular signal transduction cascades (29, 46, 50, 70). Myostatin appears to regulate skeletal muscle mass, at least in part, by inhibiting the proliferation, differentiation, and self-renewal of myoblasts (28, 39, 56, 58). Type II muscle fibers appear to be more responsive to the myostatin signaling pathway than type I muscles, but the mechanism responsible for this difference is unknown (10, 37, 41, 43).

The inhibition of myostatin may be useful in the treatment of muscle injuries and muscle-wasting diseases by improving the contractile properties of muscle (17, 26, 45, 53, 55, 59, 61). Compared with wild-type mice, myostatin-deficient mice have increased bite force (9) and gross grip strength (65). Treating mdx mice with an antibody against myostatin increased the maximum tetanic force (Po) of extensor digitorum longus (EDL) muscles, but it did not change the specific Po (sPo) (4). When mdx mice were treated with the propeptide of myostatin, both the Po and sPo of EDL muscles increased (5).

Myostatin may also be useful in treating muscle injuries and disease by regulating the collagen accumulation and scar tissue formation in the extracellular matrix (ECM) (17, 45). In addition to enhancing the contractile properties of dystrophic muscle, the deficiency of myostatin decreased the accumulation of scar tissue and ECM of mdx mice (4, 5, 63). Type I collagen is a major component of muscle ECM (31). The transcripts of two separate genes, col1{alpha}1 and col1{alpha}2, are used to synthesize the collagen I precursor molecule, procollagen I. Procollagen I is secreted into the ECM, where it undergoes cleavage and assembly to form mature collagen I (27). TGF-beta has a well-established role as a positive regulator of type I collagen protein synthesis via the Smad2/3 and p38-MAPK signaling pathways (reviewed in Ref. 60). As myostatin is a member of the TGF-beta family of cytokines and utilizes similar signal transduction pathways as TGF-beta (29, 46, 50, 70), myostatin may have a direct role in the regulation of the type I collagen content of skeletal muscle ECM.

While a few studies have examined the effects of myostatin deficiency on the contractile properties and ECM of dystrophic muscles (4, 5, 63), how myostatin deficiency impacts on healthy, nondystrophic muscle is unknown. The overall aim of this study was to determine the effect of myostatin deficiency on the contractile properties, susceptibility to contraction-induced injury, and collagen composition of skeletal muscle tissue. As increases in Po due to hypertrophy of muscle fibers often result in a corresponding decrease in sPo (15, 25, 30), we hypothesized that a deficiency of myostatin would increase the Po, but decrease the sPo. Based on the observations that myostatin deficiency decreased the ECM accumulation in dystrophic muscle (4, 5, 63), and the similarities between the myostatin and TGF-beta signal transduction pathways (29, 46, 50, 70), we formed the hypothesis that myostatin-deficient mice would have less muscle ECM and that myostatin would directly increase type I collagen expression in skeletal muscle tissue. If these assumptions proved to be correct, we hypothesized that the deficiency of myostatin would increase the force deficits of muscles following a protocol of damaging lengthening contractions.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Animals

All experiments were conducted in accordance with the guidelines of the University of Michigan Committee on the Use and Care of Animals. Mice were housed in specific pathogen-free conditions and fed food and water ad libitum. MSTN–/– mice of a C57BL/6 background were a generous gift of Dr. Se-Jin Lee. The MSTN null allele was generated by replacing the portion of the third exon of the MSTN gene that encodes the COOH-terminal region of the mature myostatin protein with a neo cassette (42). Male MSTN–/– mice were crossed with MSTN+/+ C57BL/6 female mice to generate an F1 MSTN+/– generation. The F1 generation was backcrossed to obtain an F2 generation containing all three genotypes. F2 male mice 10–12 mo of age were used in this study. The genotype of mice was determined by PCR-based analysis of genomic DNA samples obtained via tail biopsy. The MSTN wild-type allele was detected using a set of primers that generates a 247-bp amplicon from the third exon of the MSTN gene, and the MSTN null allele was detected using a set of primers that generate a 192-bp amplicon from the neo cassette that replaced the third exon of the MSTN gene. Amplicons from PCR reactions were separated on a 2% agarose gel.

Whole Muscle

Operative procedure.   Mice were anesthetized with intraperitoneal injection of Avertin (400 mg/kg). Additional doses were provided as required to maintain a deep anesthesia throughout the experiment. The EDL and soleus muscles were removed from both the left and right legs of each mouse. Muscles used for fiber counts, hydroxyproline, histochemistry, or protein analysis were flash frozen in liquid nitrogen and stored at –80°C until use. A 5–0 silk suture was tied to the proximal and distal tendons of muscles used in the contractile properties experiments. These muscles were placed immediately in a bath that contained Krebs mammalian Ringer solution with 0.25 mM tubocurarine chloride. The bath was maintained at 25°C, and the solution was bubbled with 95% O2 and 5% CO2 to stabilize pH at 7.4. Following the removal of muscles, mice were euthanized with an overdose of anesthetic and induction of a pneumothorax.

Fiber counts of muscles.   To determine the number of fibers present in muscles, the extracellular matrixes of muscles were digested as described (38). Briefly, muscles were placed in a 15% HNO3 solution overnight at room temperature. Following digestion, the HNO3 solution was replaced with phosphate-buffered saline. Individual muscle fibers were teased apart from bundles and counted under a dissecting microscope. The lengths of 40 individual fibers per muscle were measured using digital calipers.

Measurement of maximum isometric tetanic force.   Each muscle was immersed in the bath solution, and the distal tendon was attached to a servomotor (model 305B, Aurora Scientific, Aurora, ON). The proximal tendon was attached to a force transducer (model BG-50, Kulite Semiconductor Products, Leonia, NJ). The attachment of tendons to the servomotor and force transducer occurred just distal to the myotendinous junctions so that the impact of the tendon on the measurement of contractile properties was minimized. Muscles were stimulated by square pulses delivered by two platinum electrodes connected to a high-power biphasic current stimulator (model 701B, Aurora Scientific). An IBM-compatible personal computer and custom-designed software (LabVIEW 7.1, National Instruments, Austin, TX) controlled electrical pulse properties and servomotor activity and recorded data from the force transducer. The voltage of pulses was increased, and optimal muscle length (Lo) was subsequently adjusted to the length that resulted in maximum twitch force (6). The Lo was measured with digital calipers. Muscles were held at Lo and subjected to trains of pulses to generate an isometric contraction. Pulse trains were 300 ms for EDL muscles and 900 ms for soleus muscles. Stimulus frequency was increased until the Po was achieved (6). The general shape of the force traces during twitch and isometric contractions was not different between the three genotypes of mice for EDL and soleus muscles, respectively. The sPo was determined by dividing Po by the cross-sectional area (CSA). Following nitric acid digestion, both EDL and soleus muscles showed no difference in the ratio of fiber lengths (Lf) to whole muscle lengths among any of the three genotypes. Therefore the Lf-to-Lo ratios of 0.44 for EDL muscles and 0.70 for soleus muscles were used to calculate Lf (6). The physiological CSA of muscles was determined by dividing the mass of the muscle by the product of Lf and 1.06 g/cm3, the density of mammalian skeletal muscle.

Contraction-induced injury.   Following measurement of maximum twitch force and Po, a mechanical injury to muscles was produced by two 40% lengthening contractions (7, 11, 14). Muscles were stimulated and held at Lo for 100 ms for EDL muscles and 300 ms for soleus muscles to allow muscles to develop Po. Following the isometric contraction, muscles were stretched through a 40% strain relative to Lf. For the EDL a 40% strain relative to Lf plantarflexes the ankle by 12°, and for the soleus a 40% strain dorsiflexes the ankle by 16°. The velocity of the stretch was 1 Lf/s. The total time of stimulation was 500 ms. Following stimulation, muscles were returned to Lo, remained quiescent for 1 min, then were subjected to a second 40% strain. Following 1 min of rest, the Po was measured. The general shape of the force traces during lengthening contractions was not different for any of the three genotypes of mice. The average force produced during a stretch was calculated by integrating the force-time curve and dividing this value by the duration of the stretch. Work was calculated by multiplying the average force produced during a stretch by the length of the displacement and normalized by the wet mass of the muscle.

Measurement of lengths of tibias.   Hindlimbs from euthanized mice were stripped of gross muscle and connective tissue and placed in 20% hydrogen peroxide at 55°C overnight to remove remaining soft tissue. Photographic images of tibias were analyzed with ImageJ (version 1.34, NIH, Bethesda, MD) to determine length.

Hydroxyproline assay.   Hydroxyproline content of muscles was measured as described by Woessner (66). Muscles were dried for 90 min at 110°C and hydrolyzed in 500 µl of 6 M hydrochloric acid for 3.5 h. The hydrolysate was neutralized with an equal volume of 6 M sodium hydroxide. Known amounts of purified L-hydroxyproline (Sigma, St. Louis, MO) were used to construct a standard curve. Samples were assayed in triplicate using a Genios plate reader (Tecan, Mannedorf, Switzerland) at an absorbance of 560 nm.

Histology.   Muscles were cryosectioned at their midbelly and stained with Masson's trichrome. The areas of 100 muscle fibers randomly selected from sections of three muscles of each of the three genotypes were measured using ImageJ.

ActRIIB immunoblot.   Muscles that did not undergo assessments of the contractile properties were homogenized in cold Laemmli's sample buffer with 1:20 beta-mercaptoethanol and 1:20 protease inhibitor cocktail (Sigma) and then placed in boiling water for 5 min. Protein concentration of the samples was determined using an RC DC Protein Assay (Bio-Rad, Hercules, CA). Equal amounts of protein were loaded into two 4% stacking, 7.5% separating polyacrylamide gels and subjected to electrophoresis. To verify equal protein loading, gels that were not used in immunoblotting were stained with Coomassie brilliant blue (Bio-Rad). Proteins were transferred to a 0.45-µm nitrocellulose membrane and stained with Ponceau S to verify equal protein transfer. Membranes were blocked using casein and an avidin-biotin blocking kit (Vector Laboratories, Burlingame, CA), rinsed, and incubated with a biotinylated monoclonal antibody against ActRIIB (R&D Systems, Minneapolis, MN) and an avidin-horseradish peroxidase conjugate (Vector Laboratories). Membranes were developed with SuperSignal West Dura enhanced chemiluminescent reagents (Pierce Biotechnology, Rockford, IL) and visualized using a chemiluminescent documentation system (Bio-Rad).

Cultured Cells

Satellite cell isolation and culture.   Satellite cells were isolated from adult male MSTN+/+ mice as described by Allen and colleagues (1). Mice were anesthetized with intraperitoneal injection of Avertin (400 mg/kg) and killed by cervical dislocation. The hindlimb muscles were quickly removed, minced, and digested in protease solution (1.25 mg/ml of Pronase E in PBS, Sigma) for 1 h at 37°C. Satellite cells were separated from muscle fiber fragments and from tissue debris by differential centrifugation and then plated on fibronectin-coated 60-mm tissue culture plates (BD Biosciences, San Jose, CA). Cultures were maintained in a humidified environment at 37°C and 5% CO2. Satellite cells were grown in DMEM + 20% FBS + 1% antibiotic-antimycotic (AbAm) until reaching 80% confluence, at which time the media was changed to DMEM + 2% horse serum + 1% AbAm to induce differentiation into myotubes.

RT-quantitative PCR.   Myotubes were treated with different concentrations of recombinant murine myostatin (R&D Systems, Minneapolis, MN) in DMEM + 1% AbAm for 2 h. RNA was isolated from myotubes using an RNeasy Mini kit (Qiagen, Valencia, CA), treated with DNase I, and reverse transcribed using an Omniscript RT kit (Qiagen) and oligo(dT)15 primers. cDNA was amplified using primers for col1{alpha}2 (forward: 5'-CCAGCGAAGAACTCATACAGC-3'; reverse: 5'-GGACACCCCTTCTACGTTGT-3') and beta2-microglobulin (beta2m) (forward: 5'-ATGGGAAGCCGAACATACTG-3'; reverse: 5'-CAGTCTCAGTGGGGGTGAAT-3') using a SYBRgreen I PCR system (Qiagen) with Uracil DNA glycosylase (Invitrogen) in an Opticon 2 real-time thermal cycler (Bio-Rad). Quantitative PCR (qPCR) reactions were conducted in triplicate for each sample. Cycle threshold (Ct) values for col1{alpha}2 were normalized to beta2m using the 2Formula method (32). beta2m was chosen as a housekeeping gene based on its stable expression in skeletal muscle tissue (35) and because beta2m expression did not differ between treatment groups. The presence of single amplicons from qPCR reactions was verified by melting curve analysis as well as electrophoresis using a 2% agarose gel. Primers for col1{alpha}2 generate a 105-bp amplicon from exons 46 and 47 of the col1{alpha}2 gene. Intron 46–47 of the col1{alpha}2 gene is 320 bp, which would allow us to detect the presence of genomic DNA in qPCR reactions using gel electrophoresis. Genomic DNA contamination was not detected in qPCR reactions.

Procollagen I immunoblot.   Myotubes were treated with different concentrations of recombinant murine myostatin (R&D Systems) in DMEM + 1% AbAm for 8 h, rinsed with PBS and 0.5M EDTA, scraped, and homogenized in Laemmli's sample buffer with 1:20 beta-mercaptoethanol and 1:20 protease inhibitor cocktail (Sigma) and subsequently placed in boiling water for 5 min. Protein concentration, electrophoresis, and blotting occurred as described above. Membranes were blocked in 10% powdered milk, rinsed, and incubated with a polyclonal antibody against procollagen I (Santa Cruz Biotechnology, Santa Cruz, CA) and a horseradish peroxidase-conjugated secondary antibody (Pierce Biotechnology), and developed as described above. Following detection of procollagen I, membranes were stripped and reprobed using a monoclonal antibody against beta-tubulin (Developmental Studies Hybridoma Bank, Iowa City, IA).

Statistical Analyses

Results are presented as means ± SE. KaleidaGraph 4.02 software (Synergy Software, Reading, PA) was used to conduct statistical analyses. Differences between groups were tested using a one-way ANOVA with {alpha} = 0.05. Fisher's least significant difference post hoc test was used to identify specific differences when significance was detected.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Morphology

The body mass, body length, tibial length, muscle mass, absolute numbers of fibers per muscle, fiber areas, Lo, Lf, and CSA values of EDL and soleus muscles from each of the three groups of mice are shown in Table 1. Although no differences were observed for body masses or body lengths of the MSTN+/+, MSTN+/–, or MSTN–/– mice, the mean mass of the EDL muscles of MSTN–/– mice was 66% greater than that of the MSTN+/+ mice and 51% greater than that of the MSTN+/– mice. For MSTN–/– mice, the mass of the soleus was 36% greater than that of the MSTN+/+ mice.


View this table:
[in this window]
[in a new window]
  		Table 1. Anatomical properties of animals

 
Conflicting reports have been published regarding the role of myostatin in determining the number of fibers per muscle (21, 36, 42, 47, 51, 68, 69). Each of these reports counted the number of muscle fibers present in a cross section of muscle. The counting of the number of fibers present in a cross section of a muscle does not necessarily provide an accurate indication of the total number of fibers present in that muscle (38). To address this issue, the absolute number of fibers in muscles from MSTN+/+, MSTN+/–, and MSTN–/– mice was counted. The EDL muscles of MSTN–/– mice had 60% more muscle fibers than MSTN+/+ mice and 39% more fibers than MSTN+/– mice, and the MSTN+/– mice had 16% more fibers than MSTN+/+ mice (Table 1). For soleus muscles, MSTN–/– mice had 31% more fibers than MSTN+/+ mice and 9% more than MSTN+/– mice, and the MSTN+/– mice had 20% more fibers than MSTN+/+ mice (Table 1).

The mean fiber areas and CSA of EDL muscles of MSTN+/– and MSTN–/– mice were greater than that of MSTN+/+ mice. For soleus muscles, the mean fiber areas and CSA of MSTN–/– mice were greater than those of MSTN+/+ mice (Table 1).

The EDL and soleus muscles of mice both originate on the proximal tibia and run the entire length of the tibia before inserting on the phalanges or calcaneus, respectively. No differences in the lengths of tibias of MSTN+/+, MSTN+/–, and MSTN–/– mice were observed (Table 1). Furthermore, the Lo and Lf values of EDL and soleus muscles, respectively, were not different among the three genotypes.

Collagen Content of Muscles

The amino acid hydroxyproline makes up ~14% of the dry mass of fibrillar collagens (44) and is commonly used as an indicator of collagen content. The relative hydroxyproline content of EDL muscles of MSTN–/– was 75% less than that of MSTN+/+ mice (Table 1 and Fig. 1A). MSTN+/– mice had 59% less hydroxyproline than MSTN+/+ mice. For soleus muscles, no difference was observed for the relative amounts of hydroxyproline among the three genotypes (Table 1 and Fig. 1B).


Figure 1
View larger version (10K):
[in this window]
[in a new window]
  		Fig. 1. Relative hydroxyproline (Hyp) content of extensor digitorum longus (EDL; A) and soleus (B) muscles from myostatin gene MSTN+/+, MSTN+/–, and MSTN–/– mice. A: compared with MSTN+/+ mice, the amount of hydroxyproline per milligram of dry EDL muscle mass was less for MSTN+/– and MSTN–/– mice. B: there was no difference in the amount of hydroxyproline per milligram of dry soleus muscle mass between MSTN+/+, MSTN+/–, and MSTN–/– mice. Values are means ± SE; n = 5 muscles per genotype. *Significantly different from MSTN+/+, P < 0.05.

 
Myostatin-Mediated Type I Collagen Synthesis

The marked decrease in the collagen content of the EDL muscles from myostatin-deficient mice lead us to hypothesize that myostatin induces the expression of type I collagen in muscle tissue. We found a dose-dependent increase in col1{alpha}2 expression (Fig. 2A) and procollagen I protein content (Fig. 2B) of primary myotubes treated with myostatin. Similar results were observed in C2C12 myotubes and primary fibroblasts isolated from mouse tendon (data not shown).


Figure 2
View larger version (35K):
[in this window]
[in a new window]
  		Fig. 2. Myostatin increases col1{alpha}2 expression (A) and procollagen I content of primary skeletal muscle myotubes (B). A: RT-quantitative PCR. Myostatin increases the expression of col1{alpha}2 normalized to beta2-microglobulin (beta2m) in a dose-dependent fashion. Values are means ± SE. *Significantly different from the 0 ng/ml group, P < 0.05. #Significantly different from the 10 ng/ml group, P < 0.05. B: immunoblot. Myostatin increases the procollagen I protein content of myotubes in a dose-dependent fashion. beta-Tubulin is shown as a loading control.

 
Contractile Properties

Myostatin deficiency had a more profound impact on the contractile properties of EDL muscles than soleus muscles (Table 2 and Fig. 3). The Po of MSTN–/– mice was 34% greater than the Po of MSTN+/+ mice and 19% greater than the Po of MSTN+/– mice. MSTN+/– mice had a 13% greater Po than MSTN+/+ mice. When Po was normalized by the CSA, MSTN–/– mice had an 18% lower value for sPo than either MSTN+/+ or MSTN+/– mice. For soleus muscles, the Po of MSTN–/– mice was 30% greater than that of MSTN+/+ mice, but the values for sPo were not different.


View this table:
[in this window]
[in a new window]
  		Table 2. Contractile properties of EDL and soleus muscles

 

Figure 3
View larger version (23K):
[in this window]
[in a new window]
  		Fig. 3. Force values for EDL muscles (A and B) and soleus muscles (C and D) from MSTN+/+, MSTN+/–, and MSTN–/– mice. A: the maximum tetanic force (Po) of EDL muscles of MSTN–/– mice is greater than the Po of MSTN+/+ and MSTN+/– mice. B: when Po is normalized to cross-sectional area, the specific Po (sPo) of EDL muscles of MSTN–/– mice is less than the sPo of MSTN+/+ and MSTN+/– mice. C: the Po of soleus muscles of MSTN–/– mice is greater than the Po of MSTN+/+ and MSTN+/– mice. D: when Po is normalized to CSA, there is no difference in sPo of soleus muscles. Values are means ± SE; n = 6 muscles per genotype. *Significantly different from MSTN+/+, P < 0.05. #Significantly different from MSTN+/–, P < 0.05.

 
Contraction-Induced Injury

During lengthening contractions, the average force developed by EDL muscles was not different, but, compared with MSTN+/+ mice, the work done to lengthen the muscles was 12 and 37% less for MSTN+/– and MSTN–/– mice, respectively (Table 3), indicating a decrease in the stiffness of these muscles. After the lengthening contraction protocol, muscles from MSTN–/– mice had a force deficit that was 15% greater than that of MSTN+/+ mice (Table 3 and Fig. 4). During stretches of soleus muscles, the average force developed by MSTN–/– mice was ~18% greater than that of MSTN+/+ mice. During lengthening contractions of soleus muscles, no differences in the work done to stretch the muscles were observed. Following the lengthening contraction protocol, the force deficits of soleus muscles were not different.


View this table:
[in this window]
[in a new window]
  		Table 3. Mechanical injury of EDL and soleus muscles

 

Figure 4
View larger version (9K):
[in this window]
[in a new window]
  		Fig. 4. Force deficits following contraction-induced injury to EDL muscles (A) and soleus muscles (B). A: muscles from MSTN–/– mice had a force deficit that was greater than MSTN+/+ mice after the first lengthening contraction (LC), and a force deficit that was greater than MSTN+/+ and MSTN+/– mice after the second LC. B: there was no difference in the force deficits between soleus muscles following the LCs. Values are means ± SE; n = 6 muscles per genotype. *Significantly different from MSTN+/+, P < 0.05. #Significantly different from MSTN+/–, P < 0.05.

 
ActRIIB Content of EDL and Soleus Muscles

The deficiency of myostatin had a more profound impact on the morphological and contractile properties of EDL muscles than soleus muscles. Since myostatin appears to act systemically (71), the difference in the amount of ActRIIB present in EDL and soleus muscles was determined. Compared with soleus muscles, the amount of ActRIIB was greater in EDL muscles (Fig. 5).


Figure 5
View larger version (38K):
[in this window]
[in a new window]
  		Fig. 5. Activin type IIB receptor (ActRIIB) protein content of EDL and soleus muscles from MSTN+/+ mice. Compared with soleus muscles, the amount of ActRIIB protein is greater in EDL muscles (immunoblot). Sarcomeric myosin proteins are shown as loading controls (Coomassie brilliant blue staining).

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
The Po of skeletal muscle can be increased by either hypertrophy of existing fibers or by hyperplasia. In either case, as whole muscle CSA increases, the angle of pennation of muscle fibers ({theta}) also increases (38). The transmission of the force developed by single muscle fibers from tendon to tendon along the line of tension development of the muscle is proportional to the cosine of {theta}. As {theta} increases from 0 to 90°, the cosine of {theta} decreases from 1 to 0. Therefore, as a muscle undergoes hypertrophy or hyperplasia, the net force per CSA is expected to decrease. Our hypothesis that myostatin deficiency would increase the Po but decrease the sPo of muscles is supported by the observations of the contractile properties of the EDL muscles of MSTN–/– mice. In contrast, for soleus muscles, the complete deficiency of myostatin increased the Po less than that of the EDL muscle and had no effect on the sPo. Furthermore, EDL muscles of MSTN+/– mice displayed a greater Po than those of MSTN+/+ mice, but showed no change in sPo. While {theta} was not measured directly, using a model of muscle architecture that estimates {theta} based upon the number of fibers in a muscle, Lf, Lo, and fiber areas (38), compared with MSTN+/+ mice, we estimate that MSTN–/– mice had a 38% greater {theta} for EDL muscles, and a 17% greater {theta} for soleus muscles, respectively. The greater increase in {theta} for EDL than soleus muscles may explain the observed decrease in sPo for EDL muscles and the lack of change in sPo for soleus muscles. In terms of the magnitude of the increases in muscle CSA, mass, and Po, a threshold appears to exist for initiating a decrease in sPo, wherein large increases in muscle CSA, mass, and Po initiate decreases in sPo, whereas, with small increases, sPo does not change.

Following contraction-induced injury to muscles, the immediate force deficit results from the mechanical disruption of the ultrastructure of sarcomeres (8, 18, 33, 34). The magnitude of this force deficit is a function of strain and the work done to stretch the contractile component (CC) of muscle (8). The aponeurosis (intramuscular tendon) and the tendon, composed chiefly of type I and III collagen (12, 22, 27), form the series elastic component (SEC) of muscle (23). A positive correlation exists between the collagen content and stiffness of a muscle (16, 19, 48). During a lengthening contraction, the total displacement of the muscle is the sum of the displacement of the CC and the SEC; therefore, displacement of the SEC protects the CC from contraction-induced injury. During a lengthening contraction, the protection afforded to the CC by the SEC increases as the displacement of the SEC relative to the CC increases. Despite this potential for protection, if the strain and work done during a lengthening contraction are great enough, the SEC can become damaged and no longer provide protection for the CC. Consequently, an advantageous arrangement for a muscle is to have an SEC with a stiffness that allows for a moderate amount of displacement during a lengthening contraction, but not too compliant as to become damaged during a lengthening contraction. Our results suggest that, for EDL muscles, the complete deficiency of myostatin decreases the stiffness of the SEC in such a way that the susceptibility to contraction-induced injury is increased.

The effect of myostatin deficiency on the structure and function of EDL and soleus muscles was quite different. Compared with the content of the primary myostatin receptor, ActRIIB, in the soleus muscles of MSTN+/+ mice, the content in the EDL muscles was approximately twofold greater. The greater quantity of ActRIIB in the EDL muscles of MSTN+/+ mice appeared to make the EDL muscles more responsive than soleus muscles to the presence of myostatin. Consequently, with the absence of myostatin in the MSTN–/– mice, the EDL muscles experience a much greater relative increase in mass and number of fibers than experienced by the soleus muscles.

The treatment of muscle injuries and disease often involves a two-pronged therapeutic regimen of improving the strength of muscle and decreasing the formation of collagenous scar tissue (13, 49). Much of the interest behind the potential use of myostatin inhibitors is the ability of these inhibitors to enhance the regeneration of skeletal muscle and also decrease the accumulation of scar tissue in murine models of muscle injuries and disease (17, 40, 45, 61–63). Myostatin inhibitors may therefore be a useful therapeutic adjunct to traditional athletic training and physical therapy by directly improving contractility and decreasing fibrosis. The enhanced regenerative capacity of myostatin-deficient muscle is likely due to an increase in satellite cell activity, as myostatin is a negative regulator of satellite cell proliferation and migration (28, 39, 40, 56, 58, 62). The increased satellite cell activity produced by the deficiency of myostatin does not explain how myostatin deficiency decreases the fibrosis normally present in dystrophic muscle (4, 5, 63) and following snake venom-induced muscle injury (40, 62). The decreased content of collagen in otherwise healthy myostatin-deficient muscles, along with the observation that myostatin increases directly the expression of type I collagen in cultured muscle tissue, suggest a direct role for myostatin in the signal transduction pathways that regulate the collagen content of the ECM of skeletal muscle tissue.

Pharmaceutical inhibition of myostatin likely suppresses, but does not eliminate, myostatin signaling completely. The haploinsufficient MSTN+/– mouse provides a useful model for the investigation of the effects of partial suppression of myostatin signaling. In the present study, compared with their MSTN+/+ littermates, the EDL muscles of MSTN+/– mice developed a greater Po but, unlike the MSTN–/– mice, had no difference in sPo or force deficit after injury. The collagen content and stiffness of the EDL muscles of MSTN+/– mice was less than that of MSTN+/+ mice, but this did not increase the susceptibility of these muscles to contraction-induced injury. Such a decrease in the stiffness of muscle might be beneficial in the treatment of diseases that involve severe muscle fibrosis, such as Duchenne muscular dystrophy. Patients with Duchenne muscular dystrophy suffer from respiratory insufficiency due to impaired contractility of the diaphragm muscle and to the increased stiffness of the diaphragm muscle (3, 64). Therefore, partial inhibition of myostatin may provide a useful treatment for fibrotic muscle diseases through an increase in the contractile forces and a decrease in the stiffness of the muscles.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
ACKNOWLEDGMENTS
 REFERENCES
 
This work was supported by National Institute on Aging Grants AG-13283 and AG-020591.


   ACKNOWLEDGMENTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
REFERENCES
 
We acknowledge the generosity of Dr. Se-Jin Lee for providing transgenic mice for this study, Cheryl Hassett for providing assistance with animal surgeries, and Kimberly Gates for assistance with animal breeding.


   FOOTNOTES
 

Address for reprint requests and other correspondence: J. A. Faulkner, Dept. of Molecular and Integrative Physiology, Univ. of Michigan, 109 Zina Pitcher Pl., Ann Arbor, MI 48109–2007 (e-mail: jafaulk{at}umich.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 

  1. Allen RE, Temm-Grove CJ, Sheehan SM, and Rice G. Skeletal muscle satellite cell cultures. Methods Cell Biol 52: 155–176, 1997.[Web of Science][Medline]
  2. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, and Patel K. Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 270: 19–30, 2004.[CrossRef][Web of Science][Medline]
  3. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, Cornelio F, Morandi L, and Mantegazza R. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 96: 1137–1144, 1995.[Web of Science][Medline]
  4. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, and Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420: 418–421, 2002.[CrossRef][Medline]
  5. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, and Khurana TS. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19: 543–549, 2005.[Abstract/Free Full Text]
  6. Brooks SV and Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 404: 71–82, 1988.[Abstract/Free Full Text]
  7. Brooks SV and Faulkner JA. The magnitude of the initial injury induced by stretches of maximally activated muscle fibres of mice and rats increases in old age. J Physiol 497: 573–580, 1996.[Abstract/Free Full Text]
  8. Brooks SV, Zerba E, and Faulkner JA. Injury to muscle fibres after single stretches of passive and maximally stimulated muscles in mice. J Physiol 488: 459–469, 1995.[Abstract/Free Full Text]
  9. Byron CD, Hamrick MW, and Wingard CJ. Alterations of temporalis muscle contractile force and histological content from the myostatin and Mdx deficient mouse. Arch Oral Biol 51: 396–405, 2006.
  10. Carlson CJ, Booth FW, and Gordon SE. Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Am J Physiol Regul Integr Comp Physiol 277: R601–R606, 1999.[Abstract/Free Full Text]
  11. Consolino CM and Brooks SV. Susceptibility to sarcomere injury induced by single stretches of maximally activated muscles of mdx mice. J Appl Physiol 96: 633–638, 2004.[Abstract/Free Full Text]
  12. Contri MB, Guerra D, Vignali N, Taparelli F, Marcuzzi A, Caroli A, and Ronchetti IP. Ultrastructural and immunocytochemical study on normal human palmar aponeuroses. Anat Rec 240: 314–321, 1994.
  13. Delforge G. Musculoskeletal Trauma: Implications for Sports Injury Management. Champaign, IL: Human Kinetics, 2002.
  14. Dellorusso C, Crawford RW, Chamberlain JS, and Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 22: 467–475, 2001.[CrossRef][Web of Science][Medline]
  15. Donovan CM and Faulkner JA. Muscle grafts overloaded by ablation of synergistic muscles. J Appl Physiol 61: 288–292, 1986.[Abstract/Free Full Text]
  16. Ducomps C, Mauriege P, Darche B, Combes S, Lebas F, and Doutreloux JP. Effects of jump training on passive mechanical stress and stiffness in rabbit skeletal muscle: role of collagen. Acta Physiol Scand 178: 215–224, 2003.[CrossRef][Web of Science][Medline]
  17. Engvall E and Wewer UM. The new frontier in muscular dystrophy research: booster genes. FASEB J 17: 1579–1584, 2003.[Abstract/Free Full Text]
  18. Friden J and Lieber RL. Segmental muscle fiber lesions after repetitive eccentric contractions. Cell Tissue Res 293: 165–171, 1998.[CrossRef][Web of Science][Medline]
  19. Gosselin LE, Adams C, Cotter TA, McCormick RJ, and Thomas DP. Effect of exercise training on passive stiffness in locomotor skeletal muscle: role of extracellular matrix. J Appl Physiol 85: 1011–1016, 1998.[Abstract/Free Full Text]
  20. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, and Georges M. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 17: 71–74, 1997.[CrossRef][Web of Science][Medline]
  21. Grobet L, Pirottin D, Farnir F, Poncelet D, Royo LJ, Brouwers B, Christians E, Desmecht D, Coignoul F, Kahn R, and Georges M. Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. Genesis 35: 227–238, 2003.[CrossRef][Web of Science][Medline]
  22. Hanyu T, Tajima T, Takagi T, Sasaki S, Fujimoto D, Isemura M, and Yosizawa Z. Biochemical studies on the collagen of the palmar aponeurosis affected with Dupuytren's disease. Tohoku J Exp Med 142: 437–443, 1984.[Web of Science][Medline]
  23. Huijing P. Muscular force transmission: a unified, dual or multiple system? A review and some explorative experimental results. Arch Physiol Biochem 107: 292–311, 1999.[CrossRef][Web of Science][Medline]
  24. Kambadur R, Sharma M, Smith TP, and Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 7: 910–916, 1997.[Abstract/Free Full Text]
  25. Kandarian SC and White TP. Mechanical deficit persists during long-term muscle hypertrophy. J Appl Physiol 69: 861–867, 1990.[Abstract/Free Full Text]
  26. Khurana TS and Davies KE. Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov 2: 379–390, 2003.[CrossRef][Web of Science][Medline]
  27. Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev 84: 649–698, 2004.[Abstract/Free Full Text]
  28. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, and Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 277: 49831–49840, 2002.[Abstract/Free Full Text]
  29. Lee SJ and McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98: 9306–9311, 2001.[Abstract/Free Full Text]
  30. Lesch M, Parmley WW, Hamosh M, Kaufman S, and Sonnenblick EH. Effects of acute hypertrophy on the contractile properties of skeletal muscle. Am J Physiol 214: 685–690, 1968.[Free Full Text]
  31. Light N and Champion AE. Characterization of muscle epimysium, perimysium and endomysium collagens. Biochem J 219: 1017–1026, 1984.[Web of Science][Medline]
  32. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 25: 402–408, 2001.[CrossRef][Web of Science][Medline]
  33. Macpherson PC, Dennis RG, and Faulkner JA. Sarcomere dynamics and contraction-induced injury to maximally activated single muscle fibres from soleus muscles of rats. J Physiol 500: 523–533, 1997.[Abstract/Free Full Text]
  34. Macpherson PC, Schork MA, and Faulkner JA. Contraction-induced injury to single fiber segments from fast and slow muscles of rats by single stretches. Am J Physiol Cell Physiol 271: C1438–C1446, 1996.[Abstract/Free Full Text]
  35. Mahoney DJ, Carey K, Fu MH, Snow R, Cameron-Smith D, Parise G, and Tarnopolsky MA. Real-time RT-PCR analysis of housekeeping genes in human skeletal muscle following acute exercise. Physiol Genomics 18: 226–231, 2004.[Abstract/Free Full Text]
  36. Martyn JK, Bass JJ, and Oldham JM. Skeletal muscle development in normal and double-muscled cattle. Anat Rec A Discov Mol Cell Evol Biol 281: 1363–1371, 2004.[CrossRef][Medline]
  37. Matsakas A, Friedel A, Hertrampf T, and Diel P. Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta Physiol Scand 183: 299–307, 2005.[CrossRef][Web of Science][Medline]
  38. Maxwell LC, Faulkner JA, and Hyatt GJ. Estimation of number of fibers in guinea pig skeletal muscles. J Appl Physiol 37: 259–264, 1974.[Free Full Text]
  39. McCroskery S, Thomas M, Maxwell L, Sharma M, and Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162: 1135–1147, 2003.[Abstract/Free Full Text]
  40. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, Sharma M, and Kambadur R. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118: 3531–3541, 2005.[Abstract/Free Full Text]
  41. McMahon CD, Popovic L, Oldham JM, Jeanplong F, Smith HK, Kambadur R, Sharma M, Maxwell L, and Bass JJ. Myostatin-deficient mice lose more skeletal muscle mass than wild-type controls during hindlimb suspension. Am J Physiol Endocrinol Metab 285: E82–E87, 2003.[Abstract/Free Full Text]
  42. McPherron AC, Lawler AM, and Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83–90, 1997.[CrossRef][Medline]
  43. Mendler L, Zador E, Ver Heyen M, Dux L, and Wuytack F. Myostatin levels in regenerating rat muscles and in myogenic cell cultures. J Muscle Res Cell Motil 21: 551–563, 2000.[CrossRef][Web of Science][Medline]
  44. Neuman RE and Logan MA. The determination of hydroxyproline. J Biol Chem 184: 299–306, 1950.[Free Full Text]
  45. Patel K and Amthor H. The function of myostatin and strategies of myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord 15: 117–126, 2005.[CrossRef][Web of Science][Medline]
  46. Philip B, Lu Z, and Gao Y. Regulation of GDF-8 signaling by the p38 MAPK. Cell Signal 17: 365–375, 2005.[CrossRef][Web of Science][Medline]
  47. Pirottin D, Grobet L, Adamantidis A, Farnir F, Herens C, Daa Schroder H, and Georges M. Transgenic engineering of male-specific muscular hypertrophy. Proc Natl Acad Sci USA 102: 6413–6418, 2005.[Abstract/Free Full Text]
  48. Prado LG, Makarenko I, Andresen C, Kruger M, Opitz CA, and Linke WA. Isoform diversity of giant proteins in relation to passive and active contractile properties of rabbit skeletal muscles. J Gen Physiol 126: 461–480, 2005.[Abstract/Free Full Text]
  49. Prentice WE. Rehabilitation Techniques in Sports Medicine and Athletic Training. New York: McGraw-Hill, 2004.
  50. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, and Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 23: 7230–7242, 2003.[Abstract/Free Full Text]
  51. Rehfeldt C, Ott G, Gerrard DE, Varga L, Schlote W, Williams JL, Renne U, and Bunger L. Effects of the compact mutant myostatin allele Mstn (Cmpt-dl1Abc) introgressed into a high growth mouse line on skeletal muscle cellularity. J Muscle Res Cell Motil 26: 103–112, 2005.[CrossRef][Web of Science][Medline]
  52. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, Fielder TJ, and Gonzalez-Cadavid NF. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 285: E876–E888, 2003.[Abstract/Free Full Text]
  53. Roth SM and Walsh S. Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 7: 259–263, 2004.[Web of Science][Medline]
  54. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, and Lee SJ. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350: 2682–2688, 2004.[Free Full Text]
  55. Sharma M, Langley B, Bass J, and Kambadur R. Myostatin in muscle growth and repair. Exerc Sport Sci Rev 29: 155–158, 2001.[CrossRef][Medline]
  56. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH Jr, Kull FC Jr, and Gonzalez-Cadavid N. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 280: E221–E228, 2001.[Abstract/Free Full Text]
  57. Thies RS, Chen T, Davies MV, Tomkinson KN, Pearson AA, Shakey QA, and Wolfman NM. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 18: 251–259, 2001.[Web of Science][Medline]
  58. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, and Kambadur R. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 275: 40235–40243, 2000.[Abstract/Free Full Text]
  59. Tobin JF and Celeste AJ. Myostatin, a negative regulator of muscle mass: implications for muscle degenerative diseases. Curr Opin Pharmacol 5: 328–332, 2005.[CrossRef][Web of Science][Medline]
  60. Verrecchia F and Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 16: 873–880, 2004.[CrossRef][Web of Science][Medline]
  61. Wagner KR. Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol 17: 720–724, 2005.[CrossRef][Web of Science][Medline]
  62. Wagner KR, Liu X, Chang X, and Allen RE. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci USA 102: 2519–2524, 2005.[Abstract/Free Full Text]
  63. Wagner KR, McPherron AC, Winik N, and Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52: 832–836, 2002.[CrossRef][Web of Science][Medline]
  64. Wanke T, Toifl K, Merkle M, Formanek D, Lahrmann H, and Zwick H. Inspiratory muscle training in patients with Duchenne muscular dystrophy. Chest 105: 475–482, 1994.[Abstract/Free Full Text]
  65. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, and Wolfman NM. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300: 965–971, 2003.[CrossRef][Web of Science][Medline]
  66. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 93: 440–447, 1961.[CrossRef][Web of Science][Medline]
  67. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, and Lee SJ. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100: 15842–15846, 2003.[Abstract/Free Full Text]
  68. Yang J, Ratovitski T, Brady JP, Solomon MB, Wells KD, and Wall RJ. Expression of myostatin pro domain results in muscular transgenic mice. Mol Reprod Dev 60: 351–361, 2001.[CrossRef][Web of Science][Medline]
  69. Zhu X, Hadhazy M, Wehling M, Tidball JG, and McNally EM. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 474: 71–75, 2000.[CrossRef][Web of Science][Medline]
  70. Zhu X, Topouzis S, Liang LF, and Stotish RL. Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine 26: 262–272, 2004.[CrossRef][Web of Science][Medline]
  71. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, and Lee SJ. Induction of cachexia in mice by systemically administered myostatin. Science 296: 1486–1488, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Physiol. GenomicsHome page
S. Welle, A. Cardillo, M. Zanche, and R. Tawil
Skeletal muscle gene expression after myostatin knockout in mature mice
Physiol Genomics, August 7, 2009; 38(3): 342 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
O. Agbulut, A. Vignaud, C. Hourde, E. Mouisel, F. Fougerousse, G. S. Butler-Browne, and A. Ferry
Slow myosin heavy chain expression in the absence of muscle activity
Am J Physiol Cell Physiol, January 1, 2009; 296(1): C205 - C214.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
B. Blaauw, C. Mammucari, L. Toniolo, L. Agatea, R. Abraham, M. Sandri, C. Reggiani, and S. Schiaffino
Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle
Hum. Mol. Genet., December 1, 2008; 17(23): 3686 - 3696.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
H. D. Kollias and J. C. McDermott
Transforming growth factor-{beta} and myostatin signaling in skeletal muscle
J Appl Physiol, March 1, 2008; 104(3): 579 - 587.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. L. Mendias, K. I. Bakhurin, and J. A. Faulkner
Tendons of myostatin-deficient mice are small, brittle, and hypocellular
PNAS, January 8, 2008; 105(1): 388 - 393.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
101/3/898    most recent
00126.2006v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendias, C. L.
Right arrow Articles by Faulkner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendias, C. L.
Right arrow Articles by Faulkner, J. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.